Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
October 6, 2026

Atebrioz / Zilurgisertib for Fibrodysplasia Ossificans Progressiva as of October 2026

MARA Rating Company October 6, 2026

Zanvastro / zilganersen for Alexander Disease as of October 2026

MARA Rating Company October 6, 2026

Emcitate / Tiratricol for Peripheral Thyrotoxicosis in MCT8 Deficiency as of October 2026

MARA Rating Company October 6, 2026

Juvmo / Tavapadon for Parkinson’s Disease as of October 2026

MARA Rating Company October 6, 2026

Povofortay / Povorcitinib for Moderate-to-Severe Hidradenitis Suppurativa in Adults Refractory or Intolerant to Anti-TNF Therapy as of October 2026

MARA Rating Company October 6, 2026

Lyrfigtu / Lirafugratinib for Unresectable or Metastatic Cholangiocarcinoma as of October 2026

MARA Rating Company October 6, 2026

Zeydovio / Glepaglutide for Short Bowel Syndrome in Adults as of October 2026

MARA Rating Company October 6, 2026

Klygefa / Gefurulimab for Generalised Myasthenia Gravis as of October 2026

MARA Rating Company October 6, 2026

Isembyld / Apitegromab-mstn for Spinal Muscular Atrophy: Evidence Assessment for the United States, EU5, and Japan as of October 2026

MARA Rating Company October 6, 2026

Denecimig / Frehemgo for Prophylaxis of Bleeding Episodes in Haemophilia A as of October 2026

MARA Rating Company October 6, 2026